Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ACLX

Arcellx Inc

Feb 12 • 10:13AM ET

68.85

-1.03 -1.47 %

Healthcare • Biotechnology • USA • NASD

Peers: ALLO GILD CRSP NTLA FATE EDIT BLUE SGMO PSTX VCNX

| Held by: VTI XBI IWM VB VXF VBK TCAF IBB IWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	24.52%	Shs Outstand	57.78M	Perf Week	2.85%
Market Cap	3.98B	Forward P/E	-	EPS next Y	-3.37	Insider Trans	-0.52%	Shs Float	43.64M	Perf Month	3.15%
Enterprise Value	3.57B	PEG	-	EPS next Q	-1.04	Inst Own	93.32%	Short Float	20.87%	Perf Quarter	-23.70%
Income	-217.90M	P/S	110.89	EPS this Y	-102.90%	Inst Trans	1.81%	Short Ratio	8.45	Perf Half Y	-3.07%
Sales	35.90M	P/B	9.02	EPS next Y	16.94%	ROA	-30.67%	Short Interest	9.11M	Perf YTD	5.60%
Book/sh	7.63	P/C	8.63	EPS next 5Y	2.35%	ROE	-47.18%	52W High	94.07 -26.81%	Perf Year	8.74%
Cash/sh	7.98	P/FCF	-	EPS past 3/5Y	-3.30% -31.14%	ROIC	-44.92%	52W Low	47.86 43.86%	Perf 3Y	126.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	80.99%	Volatility	4.90% 4.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	99.49	EPS Y/Y TTM	-425.41%	Oper. Margin	-675.67%	ATR (14)	3.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.99	Sales Y/Y TTM	-76.96%	Profit Margin	-607.01%	RSI (14)	51.19	Recom	1.35
Dividend Gr. 3/5Y	- -	Current Ratio	3.99	EPS Q/Q	-105.12%	SMA20	0.19%	Beta	0.36	Target Price	111.94
Payout	-	Debt/Eq	0.12	Sales Q/Q	-80.99%	SMA50	1.74%	Rel Volume	0.31	Prev Close	69.88
Employees	163	LT Debt/Eq	0.10	Earnings	Nov 05 AMC	SMA200	-4.20%	Avg Volume	1.08M	Price	68.85
IPO	Feb 04, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.75% -51.96%	Trades		Volume	51,009	Change	-1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	Rothschild & Co Redburn	Buy → Neutral	$82
Jan-07-26	Resumed	UBS	Buy	$100
Dec-22-25	Initiated	Wells Fargo	Overweight	$100
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Oct-16-25	Initiated	Stifel	Buy	$129
Jun-17-25	Initiated	Citigroup	Buy	$110
Oct-08-24	Initiated	Redburn Atlantic	Buy	$109
Sep-03-24	Initiated	Cantor Fitzgerald	Overweight
May-31-24	Initiated	Piper Sandler	Overweight	$70
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36

Show Previous Ratings

Feb-04-26 09:00AM	Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder (Business Wire)
Jan-30-26 12:24AM	UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect (Insider Monkey)
Jan-21-26 04:00PM	Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings (Business Wire)
09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
07:44AM	Loading…
Dec-11-25 07:44AM	Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment (Insider Monkey)
Dec-09-25 03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com)
Dec-06-25 02:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Nov-30-25 05:42AM	CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting (Insider Monkey)
Nov-18-25 04:00PM	Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition (Business Wire)
Nov-05-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition (Business Wire)
Oct-30-25 10:00AM	Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
08:00AM	Loading…
Oct-02-25 08:00AM	Gilead's Lost Decade Is Over. It's Time to Buy the Stock. (Barrons.com)
Sep-03-25 04:00PM	Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-28-25 04:56AM	Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial (Insider Monkey)
Aug-21-25 07:57AM	Gilead dives into in vivo cell therapy with $350M buyout of Interius (BioPharma Dive)
Aug-07-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
06:49AM	EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma (Clinical Trials Arena)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-21-25 04:00PM	Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 (Business Wire) +8.26%
May-20-25 07:46AM	Baron Discovery Fund Initiated a Position in Arcellx (ACLX) (Insider Monkey)
May-14-25 09:30AM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (Business Wire)
May-12-25 08:25AM	Here's Why Arcellx (ACLX) Declined in Q1 (Insider Monkey)
May-08-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +6.27%
04:00PM	Arcellx Provides First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:51AM	Loading…
May-03-25 04:51AM	The Play On Legend Biotech (Seeking Alpha)
Apr-29-25 11:45AM	Baron Health Care Fund Q1 2025 Top Net Purchases And Sales (Seeking Alpha)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-23-25 08:49PM	Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
Apr-11-25 04:26PM	Arcellx (ACLX): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 04:00PM	Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors (Business Wire)
Feb-27-25 07:05PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.59%
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights (Business Wire)
Feb-26-25 04:00PM	Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-24-25 03:08PM	Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-19-25 10:20AM	Is Arcellx (ACLX) Poised to Capture Significant Market Share? (Insider Monkey)
Dec-27-24 02:09PM	Arcellx Stock Earns 82 Relative Strength Rating (Investor's Business Daily)
Dec-10-24 09:00PM	ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma (Clinical Trials Arena) +5.73%
Dec-09-24 04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
07:50AM	Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients (Benzinga)
Dec-08-24 11:00PM	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition (Business Wire)
Nov-13-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice (Zacks)
Nov-08-24 09:40AM	Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-07-24 05:15PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +6.65%
04:00PM	Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:41AM	Arcellx price target raised to $106 from $81 at Morgan Stanley (TipRanks)
06:27AM	Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? (Zacks)
Nov-05-24 09:00AM	Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study (Business Wire)
07:19AM	Cancer cell therapy from Arcellx, Gilead shows promise in early data (BioPharma Dive)
Oct-31-24 10:43PM	Arcellx (ACLX) Surged in Q3. Heres Why (Insider Monkey)
Aug-08-24 05:25PM	Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +12.31%
04:00PM	Arcellx Provides Second Quarter 2024 Financial Results and Business Updates (Business Wire)
Aug-02-24 06:53AM	Heres Why Arcellx (ACLX) Slipped in Q2 (Insider Monkey) -5.69%
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jun-29-24 03:08AM	Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX) (GuruFocus.com)
Jun-21-24 04:42PM	Arcellx Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-25-24 03:11AM	Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) (GuruFocus.com)
May-17-24 08:06AM	Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids (InvestorPlace)
May-15-24 07:21AM	Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Evercore ISI Starts Arcellx With Outperform Rating (MT Newswires)
May-10-24 01:13PM	Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge (GuruFocus.com) -5.67%
04:21AM	Kite and Arcellx prepare to launch Phase III multiple myeloma trial (Clinical Trials Arena)
May-09-24 10:57PM	ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:00PM	Arcellx Provides First Quarter 2024 Financial Results (Business Wire)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-07-24 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (Business Wire)
May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)
Apr-04-24 04:00PM	Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
08:40AM	How Arcellx (ACLX) Stock Stands Out in a Strong Industry (Zacks)
Mar-29-24 02:57PM	Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-27-24 01:50AM	Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares (GuruFocus.com)
Mar-20-24 04:00PM	Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 04:00PM	Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference (PR Newswire)
Feb-28-24 07:30PM	Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights (PR Newswire)
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
Dec-22-23 01:30AM	Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc (GuruFocus.com)
Dec-15-23 05:04PM	Pharmas Frontline: 3 Stocks Driving Revolutionary Drug Development (InvestorPlace)
Dec-08-23 04:00PM	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire) -6.87%
Nov-30-23 09:37PM	3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily)
Nov-16-23 10:10AM	Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead (Zacks)
Nov-15-23 04:05PM	Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead (Investor's Business Daily) +5.31%
09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
09:22AM	Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market (FierceBiotech.com)
07:16AM	Gilead expands Arcellx cancer cell therapy deal (BioPharma Dive)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lubner David Charles	Director	Jan 20 '26	Option Exercise	6.28	6,000	37,680	27,659	Jan 20 07:59 PM
Lubner David Charles	Director	Jan 20 '26	Sale	75.00	6,000	450,000	21,659	Jan 20 07:59 PM
DAVID LUBNER	Director	Jan 20 '26	Proposed Sale	68.94	15,000	1,034,100		Jan 20 04:27 PM
Heery Christopher	Officer	Jan 14 '26	Proposed Sale	68.51	5,882	402,997		Jan 14 07:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '26	Option Exercise	0.00	13,064	0	43,199	Jan 14 07:38 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 14 '26	Sale	68.51	5,882	402,997	23,749	Jan 14 07:38 PM
Heery Christopher	Officer	Jan 13 '26	Proposed Sale	65.51	7,437	487,213		Jan 13 09:24 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '26	Option Exercise	0.00	16,520	0	30,135	Jan 13 09:20 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 13 '26	Sale	65.51	7,437	487,213	29,631	Jan 13 09:20 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '26	Option Exercise	0.00	13,021	0	13,615	Jan 12 09:32 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 12 '26	Sale	64.15	6,131	393,286	37,068	Jan 12 09:32 PM
Heery Christopher	Officer	Jan 12 '26	Proposed Sale	64.15	6,131	393,286		Jan 12 07:34 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 06 '26	Option Exercise	0.00	13,064	0	43,199	Jan 06 08:25 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 03 '26	Option Exercise	0.00	16,520	0	30,135	Jan 06 08:25 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Jan 02 '26	Option Exercise	0.00	13,021	0	13,615	Jan 06 08:25 PM
Elghandour Rami	SEE REMARKS	Jan 06 '26	Option Exercise	0.00	55,991	0	782,467	Jan 06 08:15 PM
Elghandour Rami	SEE REMARKS	Jan 03 '26	Option Exercise	0.00	53,098	0	726,476	Jan 06 08:15 PM
Elghandour Rami	SEE REMARKS	Jan 02 '26	Option Exercise	0.00	55,459	0	673,378	Jan 06 08:15 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 06 '26	Option Exercise	0.00	20,530	0	64,832	Jan 06 08:14 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 03 '26	Option Exercise	0.00	15,340	0	44,302	Jan 06 08:14 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Jan 02 '26	Option Exercise	0.00	20,496	0	28,962	Jan 06 08:14 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Nov 17 '25	Sale	90.00	340	30,600	284	Nov 17 07:15 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 15 '25	Sale	91.04	5,364	488,315	8,466	Oct 15 07:28 PM
MICHELLE GILSON	Officer	Oct 15 '25	Proposed Sale	87.33	5,364	468,438		Oct 15 04:38 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 03 '25	Sale	86.00	4,882	419,870	14,894	Oct 06 07:21 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Oct 06 '25	Sale	86.22	1,064	91,733	13,830	Oct 06 07:21 PM
MICHELLE GILSON	Officer	Oct 03 '25	Proposed Sale	82.24	5,946	488,999		Oct 03 04:26 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 30 '25	Sale	81.28	21,034	1,709,723	624	Sep 30 08:16 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 29 '25	Sale	80.16	73	5,852	21,658	Sep 29 07:39 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 26 '25	Sale	80.12	12,396	993,155	21,731	Sep 26 07:45 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 18 '25	Sale	80.01	3,343	267,468	34,427	Sep 19 07:22 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Sep 19 '25	Sale	80.00	300	24,000	34,127	Sep 19 07:22 PM
CHRISTOPHER HEERY	Officer	Sep 18 '25	Proposed Sale	76.42	37,486	2,864,680		Sep 18 04:32 PM
Patel Kavita	Director	Jun 10 '25	Option Exercise	6.66	1,500	9,990	1,500	Jun 11 05:37 PM
Patel Kavita	Director	Jun 10 '25	Sale	67.36	1,500	101,040	0	Jun 11 05:37 PM
KAVITA K PATEL	Director	Jun 10 '25	Proposed Sale	66.86	1,500	100,290		Jun 10 04:25 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 23 '25	Option Exercise	0.00	22,429	0	32,011	May 28 08:18 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	May 27 '25	Sale	64.14	12,235	784,777	19,776	May 28 08:18 PM
Gilson Michelle	Officer	May 27 '25	Proposed Sale	64.14	12,235	784,776		May 27 06:50 PM
Patel Kavita	Director	May 20 '25	Option Exercise	6.66	1,500	9,990	1,500	May 20 07:58 PM
Patel Kavita	Director	May 20 '25	Sale	58.43	1,500	87,645	0	May 20 07:58 PM
Patel Kavita	Director	Apr 29 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 29 06:34 PM
Patel Kavita	Director	Apr 29 '25	Sale	64.20	1,500	96,300	0	Apr 29 06:34 PM
Yoon Derek	Director	Apr 29 '25	Proposed Sale	62.02	19,470	1,207,529		Apr 29 04:53 PM
Patel Kavita	Director	Apr 08 '25	Option Exercise	6.66	1,500	9,990	1,500	Apr 08 07:31 PM
Patel Kavita	Director	Apr 08 '25	Sale	57.50	1,500	86,250	0	Apr 08 07:31 PM
Patel Kavita	Director	Mar 18 '25	Option Exercise	6.66	1,500	9,990	1,500	Mar 18 07:01 PM
Patel Kavita	Director	Mar 18 '25	Sale	71.64	1,500	107,460	0	Mar 18 07:01 PM
Elghandour Rami	SEE REMARKS	Feb 26 '25	Sale	62.02	38,300	2,375,517	149,186	Feb 26 08:13 PM
Elghandour Rami	Officer	Feb 26 '25	Proposed Sale	62.02	38,300	2,375,517		Feb 26 08:11 PM
Patel Kavita	Director	Feb 25 '25	Option Exercise	6.66	1,500	9,990	1,500	Feb 25 07:09 PM
Patel Kavita	Director	Feb 25 '25	Sale	63.16	1,500	94,740	0	Feb 25 07:09 PM
KAVITA K PATEL	Director	Feb 25 '25	Proposed Sale	63.01	7,500	472,575		Feb 25 04:37 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 24 '25	Sale	63.79	10,155	647,773	37,486	Feb 24 08:00 PM
Heery Christopher	Officer	Feb 24 '25	Proposed Sale	63.79	10,155	647,773		Feb 24 07:57 PM

Open in Screener

IONQ

IonQ Inc

Feb 12 • 10:13AM ET

32.75

-0.86 -2.57 %

Technology • Computer Hardware • USA • NYSE

Peers: RGTI QBTS QUBT HPQ DELL IBM MSFT INTC GOOGL NVDA

| Held by: VTI VB IWM VBK VXF VGT IWO VTWO SCHM QTUM

Index	RUT	P/E	-	EPS (ttm)	-5.35	Insider Own	2.80%	Shs Outstand	354.28M	Perf Week	7.61%
Market Cap	11.60B	Forward P/E	-	EPS next Y	-1.88	Insider Trans	-2.81%	Shs Float	344.37M	Perf Month	-33.09%
Enterprise Value	10.56B	PEG	-	EPS next Q	-0.51	Inst Own	52.62%	Short Float	23.02%	Perf Quarter	-39.83%
Income	-1.47B	P/S	145.31	EPS this Y	-230.13%	Inst Trans	12.69%	Short Ratio	3.82	Perf Half Y	-20.54%
Sales	79.84M	P/B	4.69	EPS next Y	63.41%	ROA	-60.87%	Short Interest	79.28M	Perf YTD	-27.02%
Book/sh	6.99	P/C	10.72	EPS next 5Y	-4.15%	ROE	-108.23%	52W High	84.64 -61.31%	Perf Year	-13.83%
Cash/sh	3.06	P/FCF	-	EPS past 3/5Y	-42.08% -85.81%	ROIC	-63.93%	52W Low	17.88 83.14%	Perf 3Y	580.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	173.78% -	Gross Margin	-7.47%	Volatility	10.00% 9.69%	Perf 5Y	177.51%
Dividend TTM	-	EV/Sales	132.29	EPS Y/Y TTM	-555.52%	Oper. Margin	-564.39%	ATR (14)	3.61	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.31	Sales Y/Y TTM	113.07%	Profit Margin	-1836.32%	RSI (14)	33.26	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	8.73	EPS Q/Q	-1362.00%	SMA20	-20.77%	Beta	2.62	Target Price	75.50
Payout	-	Debt/Eq	0.01	Sales Q/Q	221.50%	SMA50	-29.21%	Rel Volume	1.08	Prev Close	33.61
Employees	407	LT Debt/Eq	0.01	Earnings	Feb 25 AMC	SMA200	-30.83%	Avg Volume	20.76M	Price	32.75
IPO	Jan 04, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-713.64% 47.73%	Trades		Volume	3,458,697	Change	-2.57%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Initiated	Wedbush	Outperform	$60
Dec-16-25	Initiated	Jefferies	Buy	$100
Dec-11-25	Initiated	Mizuho	Outperform	$90
Nov-20-25	Initiated	JP Morgan	Neutral	$47
Sep-15-25	Reiterated	Needham	Buy	$60 → $80
Aug-27-25	Initiated	B. Riley Securities	Buy	$61
Aug-07-25	Downgrade	DA Davidson	Buy → Neutral	$35
Jul-29-25	Initiated	Rosenblatt	Buy	$70
Jul-02-25	Initiated	Cantor Fitzgerald	Overweight	$45
Dec-19-24	Initiated	DA Davidson	Buy	$50
Aug-11-23	Reiterated	Craig Hallum	Buy	$12 → $21
Apr-26-23	Initiated	Morgan Stanley	Equal-Weight	$7
Jun-08-22	Initiated	Needham	Buy	$9
Nov-22-21	Initiated	Goldman	Neutral	$28

Show Previous Ratings

Today 08:13AM	Is Quantum Computing Stock a Buy, Hold, or Sell Amid TFLN Market Growth? (Zacks)
Feb-11-26 05:50PM	IonQ, Inc. (IONQ) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
02:00PM	Quantum Hype vs. Profits: Do NVDA and MSFT Have the Edge? (Zacks)
11:06AM	Rigetti Stock Plunges 23% YTD: Buy or Hold After Roadmap Reset? (Zacks)
Feb-09-26 09:13AM	Is IonQ Overvalued at 57x Sales? Evaluating Its M&A Strategy and Cash (Zacks)
02:00PM	Loading…
Feb-06-26 02:00PM	Quantum Computing 2026 Outlook: 2 Stocks for Long-Term Upside (Zacks) +14.99%
01:57PM	After Wolfpack Research Slammed IonQ Stock in a New Short Report, Should You Buy the Dip? (Barchart)
01:06PM	EXCLUSIVE: Why 'Neutral Atoms' Could Be Infleqtion's Secret Weapon Vs. Rigetti & IonQ (Benzinga)
10:32AM	Does Rigetti's $8.4M C-DAC Order Strengthen Its Path to Scale? (Zacks)
Feb-05-26 03:52PM	Options Corner: Insiders Are Quietly Building Exposure To IonQ Stock (Benzinga) -13.89%
02:00PM	QBTS Stock Already Down 23% in 2026: Buy or Hold as Fed Stays Tight? (Zacks)
09:46AM	A Shortseller Claims the Leading Quantum Computing Company Isn't All It Seems to Be (Barrons.com)
12:20AM	Should You Put $1,000 Into This High-Risk, High-Reward Stock Right Now? (Motley Fool)
Feb-04-26 11:02PM	2 Reasons to Watch IONQ and 1 to Stay Cautious (StockStory) -8.14%
05:50PM	Why IonQ, Inc. (IONQ) Dipped More Than Broader Market Today (Zacks)
04:24PM	Loading…
04:24PM	IonQ, the biggest quantum computing company on the stock market, disputes short-seller claims it failed to disclose holes in its revenue (Fortune)
03:35PM	Why IonQ (IONQ) Stock Is Falling Today (StockStory)
01:25PM	2 Quantum Computing Stocks to Buy Hand Over Fist in February (Motley Fool)
09:30AM	Wall Street Bulls Look Optimistic About IonQ (IONQ): Should You Buy? (Zacks)
08:00AM	IonQ to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (Business Wire)
06:17AM	Prediction: 5 Quantum Computing Stocks That Will Be Worth More Than IonQ 5 Years From Now (Motley Fool)
04:05AM	2 Top Quantum Computing Stocks to Buy in February (Motley Fool)
Feb-03-26 04:11AM	The Worst Day for Silver in 46 Years Serves as a Warning for the Stock Market's 2 Hottest Trends: AI and Quantum Computing (Motley Fool)
12:42AM	Is IonQ the Top Quantum Computing Stock to Buy Right Now? (Motley Fool)
Feb-02-26 04:03PM	2 High-Risk, High-Reward Quantum Computing Stocks to Buy Now (Barchart)
03:00PM	Quantum Stocks: February 2026 Outlook After January's Sell-Off (Zacks)
02:15PM	Should You Buy the Dip in IonQ Stock? (Barchart)
09:00AM	Investors Heavily Search IonQ, Inc. (IONQ): Here is What You Need to Know (Zacks)
08:00AM	Best-Performing Leveraged ETFs of Last Week (Zacks)
06:45AM	Better Artificial Intelligence Stock: IonQ vs. D-Wave Quantum (Motley Fool)
03:35AM	Loading…
03:35AM	Is IonQ Stock a Buy Now? (Motley Fool)
Feb-01-26 09:09AM	IonQ Inc (IONQ) Strengthening Itself Through Acquisitions (Insider Monkey)
08:19AM	Consumer Tech News (Jan 26-30): Meta Faces Lawsuits Over Youth Addiction Claims, IMF Warns AI Could Eliminate Millions Of Jobs & More (Benzinga)
01:06AM	IonQ to Buy SkyWater in $1.8B Deal, Betting on Vertically Integrated U.S. Quantum Chip Foundry (MarketBeat)
Jan-30-26 11:02PM	SkyWater Technology to Be Acquired by IonQ in $1.8B Deal to Build U.S. Quantum Chip Platform (MarketBeat) -7.54%
01:43PM	Dow Headed for 3rd-Straight Weekly Loss, February Gain (Schaeffer's Research)
11:48AM	Is IonQ Stock a Buy After Its Latest Acquisition? (Motley Fool)
10:19AM	Leidos Expands Energy Infrastructure Presence With $2.4B ENTRUST Deal (Zacks)
Jan-29-26 05:50PM	IonQ, Inc. (IONQ) Declines More Than Market: Some Information for Investors (Zacks) -5.59%
01:04PM	IonQ, Rigetti, Microsoft, Amazon, and Alphabet led Quantum Stocks Sell-Off (GuruFocus.com)
11:18AM	Defense Tech Stocks Move Higher as $15 Billion Cyber Budget Targets Quantum Threats (PR Newswire)
10:07AM	Jim Cramer Issues Urgent Profit-Taking Warning to Start 2026 (24/7 Wall St.)
Jan-28-26 09:44PM	International Business Machines Q4 Earnings Call Highlights (MarketBeat)
03:03PM	IonQ (IONQ) Stock Is Down 50%. Is This Quantum Computing Stock a Buy? (24/7 Wall St.)
03:00PM	Quantum's Next Winners? 3 Enablers With 10%+ Projected Growth in 2026 (Zacks)
02:20PM	What's Happening With IonQ Stock? (Benzinga)
08:00AM	IonQ Completes Acquisition of Skyloom, Expanding Quantum Networking and Secure Communications Capabilities (Business Wire)
04:11AM	3 Unpleasant Truths Investors in IonQ, Rigetti Computing, D-Wave Quantum, and Quantum Computing Inc. Will Have to Face in 2026 (Motley Fool)
Jan-27-26 05:15PM	Seagate (STX) Beats Q2 Earnings and Revenue Estimates (Zacks)
03:10PM	Why IonQ (IONQ) Stock Is Trading Up Today (StockStory)
03:00PM	QBTS or IONQ: Which Quantum Stock Wins After January Sell-Off? (Zacks)
02:25PM	Where Will Rigetti Computing (RGTI) Stock Be in 1 Year? (Motley Fool)
02:13PM	What's Behind The Momentum In IonQ Stock? (Benzinga)
12:31PM	D-Wave Stock Gains After $30 Million in Deals and HQ Move to Florida (Barrons.com)
11:54AM	Quantum Computing Stocks: Will IonQ's SkyWater Deal Pay Off? (Investor's Business Daily)
09:37AM	Target upgraded, Stryker downgraded: Wall Street's top analyst calls (The Fly)
08:04AM	Palantir and 5 More Stocks That Might Catch Trump's Attention-in a Good Way (Barrons.com)
08:01AM	IonQ Buys Chipmaker SkyWater In $1.8 Billion Deal (Benzinga)
07:12AM	IonQ to spend $1.8B on chipmaker SkyWater to advance US quantum computing (Manufacturing Dive)
05:56AM	IonQ to acquire SkyWater Technology in $1.8bn deal (Verdict)
02:21AM	The Zacks Analyst Blog Rigetti, D-Wave Quantum, and IonQ (Zacks)
Jan-26-26 05:20PM	If You Followed My Advice on IonQ Stock in 2025, You Doubled Your Money. Here's What I Think You Should Do Now. (Motley Fool) -8.21%
04:56PM	Stocks to Watch Monday Recap: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
04:21PM	These Stocks Are Todays Movers: USA Rare Earth, CoreWeave, Micron, Intel, Newmont, Booz Allen, IonQ, and More (Barrons.com)
04:15PM	As IonQ Snaps Up SkyWater Technology for $1.8B, Should You Buy the Quantum Computing Stock Here? (Barchart)
01:48PM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
01:25PM	IonQ Stock Falls. The Quantum Player Is Buying Chip Maker SkyWater for $1.8 Billion. (Barrons.com)
01:15PM	Quantum Firm IonQ to Buy Chipmaker SkyWater for $1.8 Billion (Bloomberg)
12:58PM	IONQ: IonQ Stock Plunges on Billion-Dollar SkyWater Acquisition (GuruFocus.com)
11:33AM	IonQ Just Bought Its Own Chip Foundry for $1.8 Billion Is This the Nvidia of Quantum? (24/7 Wall St.)
11:00AM	IonQ 2026 Investment Thesis: Technology Scale and Competition (Zacks)
10:38AM	Quantum Computing Stock Pops on $1.8B Chipmaker Buyout (Schaeffer's Research)
10:17AM	Will Strategic Partnerships Help Rigetti Reach Quantum Scale Faster? (Zacks)
09:56AM	IonQ Stock Pops. The Quantum Player Is Buying Chip Maker SkyWater for $1.8 Billion. (Barrons.com)
09:44AM	Stocks to Watch Monday: CoreWeave, American Airlines, IonQ, Enphase (The Wall Street Journal)
08:25AM	IonQ to buy SkyWater for $1.8 billion to expand hardware capabilities (Reuters)
06:46AM	IonQ Stock Pops. The Quantum Player's Buying Chip Maker SkyWater for $1.8 Billion. (Barrons.com)
06:15AM	IonQ Buys Chipmaker SkyWater In $1.8 Billion Deal (Benzinga)
06:00AM	IonQ to Acquire SkyWater Technology, Creating the Only Vertically Integrated Full-Stack Quantum Platform Company (Business Wire)
05:00AM	Quantum-Computing Company IonQ to Buy Chip Maker SkyWater for $1.8 Billion (The Wall Street Journal)
Jan-25-26 03:56PM	Want to Invest in Quantum Computing? 3 Stocks That Are Great Buys Right Now. (Motley Fool)
07:27AM	Prediction: This Quantum Computing Stock Will Skyrocket in 2026 (Motley Fool)
Jan-24-26 05:50PM	Cathie Wood's Message on Quantum Computing Stocks: Wait Another 20 to 40 Years (Motley Fool)
Jan-23-26 05:50PM	IonQ, Inc. (IONQ) Stock Declines While Market Improves: Some Information for Investors (Zacks) -8.21%
12:33PM	IonQ (IONQ) Announces that Katie Arrington Will Join Executive Team (Insider Monkey)
11:02AM	Prediction: Quantum Computing, IonQ, Rigetti, and D-Wave Will Crash In 2026. Here's What You Should Buy Instead (Motley Fool)
09:50AM	Better Quantum Computing Stock: D-Wave Quantum vs. IonQ (Motley Fool)
07:05AM	IonQ Could Be One of the Most Important Tech Stocks of the Next Decade (Motley Fool)
06:17AM	This Analyst Thinks Rigetti Stock Could Climb 40% -- Should You Buy RGTI Now? (GuruFocus.com)
01:35AM	The Simple Reason Why I Won't Buy Quantum Computing Stocks in 2026 (Motley Fool)
Jan-22-26 10:03PM	The Best Stocks to Buy With $1,000 Right Now (Motley Fool)
12:01PM	QBTS Soars 332% in a Year: Quantum Revenue Growth to Continue in 2026? (Zacks)
07:45AM	3 Millionaire-Maker Technology Stocks Worth a Closer Look (Motley Fool)
04:26AM	Investors Are Overlooking a Monumental Headwind With Quantum Computing Stocks IonQ and Rigetti Computing (Motley Fool)
Jan-21-26 06:00PM	IonQ, Inc. (IONQ) Stock Dips While Market Gains: Key Facts (Zacks)
04:05AM	A Once-in-a-Decade Investment Opportunity: 3 Quantum Computing Stocks to Buy and Hold (Motley Fool)
Jan-20-26 12:52PM	What's Going On With Rigetti Stock Today? (Benzinga)
12:02PM	Is Rigetti's Chiplet Strategy Accelerating the 1,000-Qubit Roadmap? (Zacks)
10:44AM	3 Key Ways D-Wave Is Developing an Advantage in Quantum Computing (MarketBeat)
07:20AM	Could IonQ Become the Nvidia of Quantum Computing? (Motley Fool)

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chou Kathryn K.	Director	Dec 22 '25	Option Exercise	4.61	5,000	23,050	65,839	Dec 23 09:55 PM
Chou Kathryn K.	Director	Dec 22 '25	Sale	55.00	5,000	275,000	60,839	Dec 23 09:55 PM
KATHRYN CHOU	Director	Dec 22 '25	Proposed Sale	48.48	5,000	242,400		Dec 22 04:28 PM
Chou Kathryn K.	Director	Dec 11 '25	Option Exercise	4.61	20,000	92,200	80,839	Dec 12 09:55 PM
Chou Kathryn K.	Director	Dec 11 '25	Sale	51.40	20,000	1,027,980	60,839	Dec 12 09:55 PM
KATHRYN CHOU	Director	Dec 11 '25	Proposed Sale	51.67	20,000	1,033,400		Dec 11 04:24 PM
RIMA ALAMEDDINE	Officer	Dec 11 '25	Proposed Sale	51.56	73,155	3,772,121		Dec 11 04:15 PM
Dacier Paul T.	Officer	Dec 11 '25	Proposed Sale	52.69	4,490	236,578		Dec 10 04:05 PM
Alameddine Rima	Officer	Dec 11 '25	Proposed Sale	52.69	230,090	12,123,442		Dec 10 04:05 PM
Millard Scott	Officer	Dec 11 '25	Proposed Sale	52.69	24,030	1,266,141		Dec 10 04:05 PM
de Masi Niccolo	Officer	Dec 11 '25	Proposed Sale	52.69	17,690	932,086		Dec 10 04:05 PM
Singh Inder M.	Officer	Dec 11 '25	Proposed Sale	52.69	15,420	812,480		Dec 10 04:05 PM
RIMA ALAMEDDINE	Officer	Dec 09 '25	Proposed Sale	53.74	133,615	7,181,125		Dec 09 04:17 PM
RIMA ALAMEDDINE	Officer	Dec 04 '25	Proposed Sale	48.65	25,000	1,216,250		Dec 04 04:42 PM
Thomas Kramer	former employee	Dec 03 '25	Proposed Sale	46.50	1,400,000	65,098,758		Dec 03 04:09 PM
RIMA ALAMEDDINE	Officer	Nov 28 '25	Proposed Sale	46.90	25,000	1,172,500		Nov 28 01:21 PM
Alameddine Rima	Chief Revenue Officer	Nov 20 '25	Sale	46.89	100,000	4,689,060	432,616	Nov 21 09:00 PM
RIMA ALAMEDDINE	Officer	Nov 20 '25	Proposed Sale	47.88	100,000	4,788,000		Nov 20 04:22 PM
TEUBER WILLIAM J JR	Director	Nov 11 '25	Buy	54.81	2,000	109,630	6,413	Nov 13 09:00 PM
Peter Chapman	Affiliate	Oct 07 '25	Proposed Sale	79.99	814,601	65,157,739		Oct 07 04:32 PM
Cardillo Robert T.	Executive Chair, IonQ Federal	Sep 12 '25	Option Exercise	11.24	8,773	98,609	46,209	Sep 16 09:00 PM
Cardillo Robert T.	Executive Chair, IonQ Federal	Sep 12 '25	Sale	50.52	8,773	443,192	37,436	Sep 16 09:00 PM
DACIER PAUL T	Chief Administrative Officer	Sep 11 '25	Sale	44.40	4,175	185,377	114,454	Sep 12 09:00 PM
Alameddine Rima	Chief Revenue Officer	Sep 11 '25	Sale	44.40	19,976	886,966	532,616	Sep 12 09:00 PM
de Masi Niccolo	President and CEO	Sep 11 '25	Sale	44.40	16,120	715,754	1,181,186	Sep 12 09:00 PM
THOMAS G. KRAMER	Officer	Sep 12 '25	Proposed Sale	47.05	129,670	6,100,974		Sep 12 04:32 PM
ROBERT CARDILLO	Director	Sep 12 '25	Proposed Sale	47.05	8,773	412,770		Sep 12 04:31 PM
de Masi Niccolo	Officer	Sep 11 '25	Proposed Sale	44.00	20,470	900,680		Sep 11 04:18 PM
Dacier Paul T.	Officer	Sep 11 '25	Proposed Sale	44.00	5,120	225,280		Sep 11 04:00 PM
Alameddine Rima	Officer	Sep 11 '25	Proposed Sale	44.00	25,370	1,116,280		Sep 11 04:00 PM
Kramer Thomas G.	Chief Financial Officer	Sep 03 '25	Sale	41.82	64,578	2,700,859	473,302	Sep 05 09:00 PM
THOMAS G. KRAMER	Officer	Sep 03 '25	Proposed Sale	42.99	158,330	6,806,607		Sep 03 04:35 PM
Singh Inder M	Director	Aug 13 '25	Option Exercise	12.81	50,480	646,842	55,993	Aug 15 09:00 PM
Singh Inder M	Director	Aug 13 '25	Sale	43.02	50,480	2,171,801	5,513	Aug 15 09:00 PM
Chapman Peter Hume	Officer	Aug 15 '25	Proposed Sale	41.21	85,510	3,523,868		Aug 15 04:00 PM
INDER SINGH	Officer	Aug 13 '25	Proposed Sale	43.02	50,480	2,171,801		Aug 13 04:18 PM
Kramer Thomas G.	Chief Financial Officer	Aug 06 '25	Sale	41.28	17,776	733,800	537,880	Aug 08 09:00 PM
Singh Inder M	Director	Aug 01 '25	Option Exercise	5.72	10,000	57,200	42,603	Aug 05 09:00 PM
Singh Inder M	Director	Aug 01 '25	Sale	38.28	37,090	1,419,891	5,513	Aug 05 09:00 PM
Kramer Thomas G.	Chief Financial Officer	Jul 21 '25	Sale	47.70	47,478	2,264,720	555,656	Jul 23 09:00 PM
Chou Kathryn K.	Director	Jul 11 '25	Sale	43.14	6,789	292,864	60,839	Jul 15 09:00 PM
KATHRYN CHOU	Director	Jul 11 '25	Proposed Sale	45.93	6,789	311,819		Jul 11 04:17 PM
Kramer Thomas G.	Chief Financial Officer	Jul 08 '25	Sale	47.73	43,382	2,070,584	603,134	Jul 10 09:00 PM
Alameddine Rima	Chief Revenue Officer	Jul 07 '25	Option Exercise	4.65	45,000	209,250	597,592	Jul 07 09:00 PM
Alameddine Rima	Chief Revenue Officer	Jul 07 '25	Sale	46.18	45,000	2,078,100	552,592	Jul 07 09:00 PM
Kramer Thomas G.	Chief Financial Officer	Jul 02 '25	Sale	42.26	72,000	3,042,396	646,516	Jul 07 09:00 PM
Chou Kathryn K.	Director	Jul 07 '25	Option Exercise	4.61	5,000	23,050	72,628	Jul 07 09:00 PM
Chou Kathryn K.	Director	Jul 07 '25	Sale	46.18	5,000	230,900	67,628	Jul 07 09:00 PM
RIMA ALAMEDDINE	Officer	Jul 07 '25	Proposed Sale	44.39	45,000	1,997,550		Jul 07 04:17 PM
Chapman Peter Hume	Executive Chair	Jun 20 '25	Option Exercise	0.13	1,497,311	199,741	1,887,640	Jun 20 09:00 PM
Chapman Peter Hume	Executive Chair	Jun 20 '25	Sale	39.93	1,497,311	59,789,126	390,329	Jun 20 09:00 PM
Chapman Peter Hume	Officer	Jun 20 '25	Proposed Sale	39.87	1,497,311	59,699,293		Jun 20 04:11 PM
Kramer Thomas G.	Chief Financial Officer	Jun 16 '25	Sale	38.11	216,000	8,232,430	718,516	Jun 18 09:00 PM
Chapman Peter Hume	Executive Chair	Jun 16 '25	Option Exercise	0.13	3,581,193	477,731	3,971,522	Jun 18 09:00 PM
Chapman Peter Hume	Executive Chair	Jun 17 '25	Option Exercise	0.13	910,740	121,493	1,301,069	Jun 18 09:00 PM
Chapman Peter Hume	Executive Chair	Jun 16 '25	Sale	38.13	3,581,193	136,536,564	390,329	Jun 18 09:00 PM
Chapman Peter Hume	Executive Chair	Jun 17 '25	Sale	37.78	910,740	34,406,573	390,329	Jun 18 09:00 PM
Chapman Peter Hume	Officer	Jun 17 '25	Proposed Sale	37.78	910,740	34,404,703		Jun 17 04:15 PM
Chapman Peter Hume	Officer	Jun 16 '25	Proposed Sale	38.13	3,581,193	136,536,638		Jun 16 04:39 PM
THOMAS G. KRAMER	Officer	Jun 16 '25	Proposed Sale	37.84	432,000	16,346,880		Jun 16 04:29 PM
Thomas Wendy	Director	Jun 12 '25	Option Exercise	4.62	5,000	23,100	77,841	Jun 13 09:00 PM
Thomas Wendy	Director	Jun 12 '25	Sale	39.43	16,696	658,297	61,145	Jun 13 09:00 PM
Chapman Peter Hume	Executive Chair	Jun 11 '25	Sale	41.60	11,965	497,689	390,329	Jun 13 09:00 PM
Chou Kathryn K.	Director	Jun 11 '25	Option Exercise	4.61	14,000	64,540	87,811	Jun 13 09:00 PM
Chou Kathryn K.	Director	Jun 11 '25	Sale	40.46	25,696	1,039,768	62,115	Jun 13 09:00 PM
Cardillo Robert T.	Director	Jun 11 '25	Sale	40.22	10,058	404,578	31,923	Jun 13 09:00 PM
TOLEDANO GABRIELLE B	Director	Jun 11 '25	Sale	41.50	792	32,868	792	Jun 13 09:00 PM
de Masi Niccolo	President and CEO	Jun 11 '25	Sale	40.34	2,597,500	104,793,280	0	Jun 13 09:00 PM
Alameddine Rima	Chief Revenue Officer	Jun 13 '25	Option Exercise	4.65	65,000	302,250	617,592	Jun 13 09:00 PM
Alameddine Rima	Chief Revenue Officer	Jun 13 '25	Sale	38.57	65,000	2,506,758	552,592	Jun 13 09:00 PM
Alameddine Rima	Chief Revenue Officer	Jun 11 '25	Sale	41.60	19,976	830,910	552,592	Jun 13 09:00 PM
Kramer Thomas G.	Chief Financial Officer	Jun 11 '25	Sale	41.60	9,994	415,704	934,516	Jun 13 09:00 PM
Singh Inder M	Director	Jun 12 '25	Option Exercise	5.72	10,000	57,200	70,481	Jun 13 09:00 PM
Singh Inder M	Director	Jun 12 '25	Sale	39.18	43,391	1,699,873	27,090	Jun 13 09:00 PM
RIMA ALAMEDDINE	Officer	Jun 13 '25	Proposed Sale	38.71	65,000	2,516,150		Jun 13 04:41 PM
WENDY THOMAS	Director	Jun 12 '25	Proposed Sale	39.70	16,696	662,831		Jun 12 04:19 PM
INDER SINGH	Director	Jun 12 '25	Proposed Sale	39.70	80,481	3,195,096		Jun 12 04:19 PM
GABRIELLE B TOLEDANO	Director	Jun 11 '25	Proposed Sale	39.74	792	31,474		Jun 11 04:31 PM
ROBERT CARDILLO	Director	Jun 11 '25	Proposed Sale	39.74	10,058	399,705		Jun 11 04:31 PM
KATHRYN CHOU	Director	Jun 11 '25	Proposed Sale	39.74	32,485	1,290,954		Jun 11 04:30 PM
ISALEA INVESTMENTS LP	Director	Jun 11 '25	Proposed Sale	39.74	2,597,500	103,224,650		Jun 11 04:30 PM
de Masi Niccolo	President and CEO	Jun 09 '25	Sale	42.23	9,280	391,894	711,987	Jun 10 09:00 PM
Kramer Thomas G.	Officer	Jun 11 '25	Proposed Sale	39.02	13,910	542,769		Jun 09 09:00 PM
Alameddine Rima	Officer	Jun 11 '25	Proposed Sale	39.02	28,540	1,113,631		Jun 09 09:00 PM
Chapman Peter Hume	Officer	Jun 11 '25	Proposed Sale	39.02	16,850	657,487		Jun 09 09:00 PM
de Masi Niccolo	Officer	Jun 09 '25	Proposed Sale	36.66	13,320	488,312		Jun 06 09:00 PM
You Harry L.	Director	May 09 '25	Proposed Sale	32.14	16,091	517,119		May 09 05:17 PM
Alameddine Rima	Chief Revenue Officer	Mar 11 '25	Sale	18.57	20,047	372,263	572,568	Mar 13 09:00 PM
Chapman Peter Hume	Executive Chair	Mar 11 '25	Sale	18.57	12,069	224,115	402,294	Mar 13 09:00 PM
Kramer Thomas G.	Chief Financial Officer	Mar 11 '25	Sale	18.57	11,712	217,486	944,510	Mar 13 09:00 PM
Scannell William F	Director	Mar 12 '25	Buy	21.81	93,066	2,029,509	135,047	Mar 12 09:18 PM
Chapman Peter Hume	Executive Chair	Mar 11 '25	Option Exercise	1.90	2,000,000	3,797,045	2,414,363	Mar 11 09:47 PM
Chapman Peter Hume	Executive Chair	Mar 11 '25	Sale	18.72	2,000,000	37,446,600	414,363	Mar 11 09:47 PM
Chapman Peter Hume	Officer	Mar 11 '25	Proposed Sale	18.72	2,000,000	37,446,614		Mar 11 04:16 PM
Alameddine Rima	Chief Revenue Officer	Mar 06 '25	Sale	21.20	1,407	29,834	592,615	Mar 10 09:00 PM
Kramer Thomas G.	Officer	Mar 11 '25	Proposed Sale	20.48	15,930	326,247		Mar 10 09:00 PM
Alameddine Rima	Officer	Mar 11 '25	Proposed Sale	20.48	28,540	584,500		Mar 10 09:00 PM
Chapman Peter Hume	Officer	Mar 11 '25	Proposed Sale	20.48	16,850	345,088		Mar 10 09:00 PM
Alameddine Rima	Officer	Mar 06 '25	Proposed Sale	23.11	1,680	38,825		Mar 05 09:00 PM

ACLX

Arcellx Inc

IONQ

IonQ Inc

Upgrade your FINVIZ experience